Stacie L. Ropka, Ph.D., J.D., Counsel, Axinn, Veltrop & Harkrider LLP to Speak at KC’s Event

New York, NY, August 29, 2015 --(PR.com)-- The Knowledge Group/The Knowledge Congress Live Webcast Series, the leading producer of regulatory focused webcasts, has announced today Stacie L. Ropka, Ph.D., J.D., Counsel, Axinn, Veltrop & Harkrider LLP will speak at the Knowledge Congress’ webcast entitled “BPCIA Litigation: Latest Developments for 2015 and Beyond LIVE Webcast” This event is scheduled for Tuesday, September 1, 2015 @ 12:00 PM to 2:00 PM (ET).

For further details, please visit:

https://theknowledgegroup.org/event_name/bpcia-litigation-latest-developments-for-2015-and-beyond-live-webcast/

About Stacie L. Ropka, Ph.D., J.D

Stacie Ropka holds a PhD in Microbiology and Immunology. Her practice is focused on IP litigation, due diligence and client counseling with an emphasis on the life sciences, biologics and biologic-based pharmaceuticals. Stacie keeps abreast of the technology and related law by regularly attending both scientific and legal conferences.

Prior to becoming a lawyer, Stacie held a faculty position at SUNY Upstate Medical University. She also spent many years as a research scientist in the fields of neurology, virology and immunology, both at Northwestern University and SUNY Upstate Medical University, and has presented her original research at numerous scientific conferences.

Stacie is a member of the American Bar Association, The American Society for Microbiology and The Antibody Society.

About Axinn, Veltrop & Harkrider LLP

Axinn’s Biotech and Life Sciences practice provides counseling services and pre-litigation strategies to assist clients in the selection, development, approval and marketing of technologies and therapies targeted to cancer, autoimmune disease and reconstructive surgery.

Axinn’s life sciences team includes attorneys who have garnered experience as bench scientists; teachers of medicine and medical device invention and design; research and formulation scientists; biomedical, genetic and process development engineers; members of professional societies for engineers and scientists; scientific authors and sought-out media analysts; and litigators with extensive trial experience. In addition, Axinn’s biotechnology and life sciences team is well-versed in all aspects of the Biologics Price Competition and Innovation Act (BPCIA), and regularly guides clients through the complex patent and noticing provisions of the BPCIA.

KC Event Synopsis:

Five years after the Biologics Price Competition and Innovation Act (BPCIA) has been passed into law, litigation related to the patent resolution procedure for biosimilars has begun to rise.

In a two-hour live Webcast, a panel of thought leaders and practitioners assembled by The Knowledge Group will offer an in-depth discussion of the significant and latest issues surrounding BPCIA. Speakers will examine the new BPCIA legal framework created to resolve patent disputes between biosimilar makers and patent holders as well the updates to recent biosimilar-related cases.

Key issues that will be covered in this course are:
- Biologics Price Competition and Innovation Act (BPCIA) – An Overview
- Latest Framework for Biosimilar Patent-Related Dispute Resolution
- Recent Developments to BPCIA Litigation such as:
- Otsuka Pharmaceutical Co., Ltd. v. FDA
- Amgen Inc. v. Sandoz Inc.
- Appeal of Amgen’s Request to Block Sales of Zarxio

About The Knowledge Group/The Knowledge Congress Live Webcast Series

The Knowledge Congress is a series of live webcasts produced by The Knowledge Group, which examine trends, regulatory, and technology changes across a variety of industries. For further details, please visit: http://theknowledgegroup.org.